Crinetics reports Q4 PALSONIFY U.S. preliminary net product revenue of over $5M

Crinetics (CRNX) Pharmaceuticals announced PALSONIFY U.S. unaudited and preliminary net product revenue of over $5M for fourth-quarter 2025. Crinetics also announced “positive” topline results from the fourth cohort of its Phase 2 congenital adrenal hyperplasia study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome. “I’m very proud of our team’s strong execution of Palsonify’s launch in acromegaly. We are delivering impressive results, highlighted by over 200 enrollment forms in the first three months after FDA approval, a broad prescriber base, and continued momentum toward favorable payer coverage. Further, we are excited to announce additional positive atumelnant clinical data which reinforces its potential to become an uncompromising, highly differentiated treatment for people struggling with CAH. Today’s launch update and clinical results mark two major steps forward for becoming the premier global endocrine company and to advance our unique portfolio that has been purposefully built to redefine the standard of care for people struggling with endocrine and endocrine-related diseases,” said Scott Struthers, Ph.D., founder and CEO of Crinetics.